Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:sssptau125rxt
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS	3	Feb 06	Engineering Information Encompass files have new names
NEWS	4	Feb 16	TOXLINE no longer being updated
NEWS	5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS	6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS	7	May 07	DGENE Reload
NEWS	8	Jun 20	Published patent applications (A1) are now in USPATFULL
NEWS	9	JUL 13	New SDI alert frequency now available in Derwent's DWPI and DPCI

NEWS EXPRESS	July 11 CURRENT WINDOWS VERSION IS V6.0b, CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP), AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:05:27 ON 23 JUL 2001

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 12:05:31 ON 23 JUL 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 22 JUL 2001 HIGHEST RN 347357-94-2
DICTIONARY FILE UPDATES: 22 JUL 2001 HIGHEST RN 347357-94-2

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

```
=> e niacin

E1            1     NIACET/BI
E2            2     NIACIDE/BI
E3           15 --> NIACIN/BI
E4            5     NIACINAMIDE/BI
E5            3     NIACINATE/BI
E6            2     NIACINI/BI
E7            1     NIACOL/BI
E8            5     NIACYCLO/BI
E9            1     NIACYCLODODECA/BI
E10           1     NIACYCLODODECANE/BI
E11           3     NIACYCLOPENT/BI
E12          21     NIAD/BI

=> s e3

L1           15 NIACIN/BI

=> s niacin

L2           15 NIACIN

=> e niacin

E1            1     NIACET/BI
E2            2     NIACIDE/BI
E3           15 --> NIACIN/BI
E4            5     NIACINAMIDE/BI
E5            3     NIACINATE/BI
E6            2     NIACINI/BI
E7            1     NIACOL/BI
E8            5     NIACYCLO/BI
E9            1     NIACYCLODODECA/BI
E10           1     NIACYCLODODECANE/BI
E11           3     NIACYCLOPENT/BI
E12          21     NIAD/BI

=> s e4

L3            5 NIACINAMIDE/BI

=> file caplus

COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              12.02      12.17

FILE 'CAPLUS' ENTERED AT 12:06:43 ON 23 JUL 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1947 - 23 Jul 2001 VOL 135 ISS 5
FILE LAST UPDATED: 22 Jul 2001 (20010722/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

=> d his

(FILE 'HOME' ENTERED AT 12:05:27 ON 23 JUL 2001)

FILE 'REGISTRY' ENTERED AT 12:05:31 ON 23 JUL 2001
E NIACIN
L1 15 S E3
L2 15 S NIACIN
E NIACIN
L3 5 S E4

FILE 'CAPLUS' ENTERED AT 12:06:43 ON 23 JUL 2001

=> s l1

L4 13365 L1

=> s l3

L5 5592 L3

=> s hiv or retrovirus

39133 HIV
10264 RETROVIRUS
L6 48143 HIV OR RETROVIRUS

=> s l4 and l6

L7 30 L4 AND L6

=> d l7 1-30

L7 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 2001:294981 CAPLUS
DN 134:311436
TI Methods of preparing novel dipeptides with **HIV** protease inhibitory activity
IN Kato, Ryohei; Mimoto, Tsutomu; Fukazawa, Tominaga; Morohashi, Naoko; Kiso, Yoshiaki
PA Japan Energy Corporation, Japan
SO U.S., 25 pp., Cont.-in-part of U.S. 5,932,550.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6222043	B1	20010424	US 1999-228009	19990108
	US 5932550	A	19990803	US 1996-669757	19960626
	ZA 9605472	A	19970127	ZA 1996-5472	19960627
	US 5962640	A	19991005	US 1998-137608	19980821
PRAI	JP 1995-188151	A	19950630		
	JP 1996-140678	A	19960510		
	US 1996-669757	A2	19960626		

OS MARPAT 134:311436
RE.CNT 45
RE
(1) Anderson; US 5126326 1992 CAPLUS
(2) Anderson; US 5212157 1993 CAPLUS
(3) Anon; EP 0394853 1990 CAPLUS
(4) Anon; EP 0438311 A2 1991 CAPLUS
(5) Anon; EP 0490667 A2 1992 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 2001:265385 CAPLUS
DN 134:295739
TI Preparation of N-aryl-N-(heterocyclylalkyl)piperidinecarboxamides as CCR5 antagonists
IN Imamura, Shinichi; Hashiguchi, Shohei; Hattori, Taeko; Nishimura, Osamu; Kanzaki, Naoyuki; Baba, Masanori; Sugihara, Yoshihiro
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 392 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001025200	A1	20010412	WO 2000-JP6755	20000929
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 1999-282088	A	19991001		

JP 2000-46749 A 20000218
OS MARPAT 134:295739
RE.CNT 6
RE
(1) Bhuniya; CAPLUS
(2) Bhuniya; SYNTH COMMUN 1994, V24(3), P375 CAPLUS
(3) Bolhofer, W; US 4203988 A 1980 CAPLUS
(4) Pharmaceutical Discovery Corp; WO 9422861 A 1994 CAPLUS
(5) Porter, R; WO 9917773 A 1999 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 2001:6065 CAPLUS
DN 134:37051
TI Method for immune-system strengthening and development of a lipid transporter for anti-**HIV** and antibacterial gene therapy
IN Worm, Richard; Correa, Michel; Mavoungou, Donatien
PA Can.
SO Fr. Demande, 16 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2792201	A1	20001020	FR 1999-4706	19990415

L7 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 2000:220728 CAPLUS
DN 132:265504
TI Preparation of hydroxyethylamino sulfonamides useful as retroviral protease inhibitors.
IN Vazquez, Michael L.; Mueller, Richard A.; Talley, John J.; Getman, Daniel P.; Decrescenzo, Gary A.; Freskos, John N.; Bertebshaw, Deborah E.; Heintz, Robert M.
PA Searle and Co., USA
SO U.S., 119 pp., Cont.-in-part of U.S. 204,872, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6046190	A	20000404	US 1996-586866	19960124
WO 9404492	A1	19940303	WO 1993-US7814	19930824
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 810209	A2	19971203	EP 1997-113434	19930824
EP 810209	A3	19981202		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
WO 9506030	A1	19950302	WO 1994-US9139	19940823
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US, UZ, VN				
RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PRAI US 1992-934984	B2	19920825		
WO 1993-US7814	A2	19930824		

US 1994-204872 B2 19940302
WO 1994-US9139 W 19940823
EP 1993-923714 A3 19930824
US 1993-110911 A 19930824
US 1994-204827 A 19940302
OS MARPAT 132:265504
RE.CNT 45
RE
(1) Anon; EP 104041 1980 CAPLUS
(2) Anon; EP 172347 1980 CAPLUS
(3) Anon; EP 223437 1980 CAPLUS
(4) Anon; WO 8403044 1984 CAPLUS
(5) Anon; GB 2184730 1987 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 2000:29393 CAPLUS
DN 133:16730
TI Niacin as a potential AIDS preventive factor
AU Murray, M. F.
CS HIV/AIDS Service, Department of Medicine, Tewksbury Hospital, Tewksbury, MA, 01876, USA
SO Med. Hypotheses (1999), 53(5), 375-379
CODEN: MEHYDY; ISSN: 0306-9877
PB Churchill Livingstone
DT Journal; General Review
LA English
RE.CNT 44
RE
(3) Bofill, M; J Biol Chem 1995, V270, P29690 CAPLUS
(5) Carlucci, F; Biomed Pharmacother 1996, V50, P158 CAPLUS
(9) Deterre, P; J Immunol 1996, V157, P1381 CAPLUS
(10) DiPalma, J; Annu Rev Nutr 1991, V11, P169 CAPLUS
(15) Fuchs, D; Immun Lett 1991, V28, P207 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1999:670116 CAPLUS
DN 131:295568
TI .alpha.- and .beta.-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
IN Vazques, Michael L.; Mueller, Richard A.; Talley, John J.; Getman, Daniel P.; Decrescenzo, Gary A.; Freskos, John N.; Bertenshaw, Deborah E.; Heintz, Robert M.
PA G. D. Searle and Co., USA
SO U.S., 130 pp., Cont.-in-part of U. S. 204,827.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5968942	A	19991019	US 1994-294468	19940823
	WO 9404492	A1	19940303	WO 1993-US7814	19930824
	W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	EP 810209	A2	19971203	EP 1997-113434	19930824
	EP 810209	A3	19981202		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
	US 6060476	A	20000509	US 1994-204827	19940302

```
     US 6248775         B1   20010619       US 1999-288080   19990408
PRAI US 1992-934984     B2   19920825
     WO 1993-US7814     A2   19930824
     US 1994-204827     A2   19940302
     EP 1993-923714     A3   19930824
     US 1993-110911     A2   19930824
     US 1994-294468     A1   19940823
OS   MARPAT 131:295568
RE.CNT  44
RE
(1) Anon; EP 0104041 1984 CAPLUS
(2) Anon; EP 0114993 1984 CAPLUS
(3) Anon; EP 0172347 1986 CAPLUS
(4) Anon; EP 0223437 1987 CAPLUS
(5) Anon; GB 2184730 1987 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7   ANSWER 7 OF 30  CAPLUS  COPYRIGHT 2001 ACS
AN   1999:464280  CAPLUS
DN   131:116153
TI   Preparation of N-(phenylcyclopropyl)-N'-pyridylurea derivatives as
     antivirals and as HIV reverse transcriptase inhibitors
IN   Sahlberg, Christer; Noreen, Rolf; Hogberg, Marita; Engelhardt, Per
PA   Medivir AB, Swed.
SO   PCT Int. Appl., 86 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   WO 9936406          A1   19990722       WO 1999-SE53     19990115
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
             MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
             TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 9924450          A1   19990802       AU 1999-24450    19990115
     EP 1054867          A1   20001129       EP 1999-903983   19990115
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
PRAI SE 1998-113        A    19980116
     SE 1998-116        A    19980116
     WO 1999-SE53       W    19990115
OS   MARPAT 131:116153
RE.CNT  1
RE
(1) Medivir Ab; WO 9506034 A1 1995 CAPLUS

L7   ANSWER 8 OF 30  CAPLUS  COPYRIGHT 2001 ACS
AN   1998:661494  CAPLUS
DN   129:298375
TI   Antimicrobial prevention and treatment of human immunodeficiency virus
and
     other infectious diseases
IN   Squires, Meryl
PA   USA
SO   PCT Int. Appl., 99 pp.
     CODEN: PIXXD2
```

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9842188	A1	19981001	WO 1998-US5792	19980324
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9867718	A1	19981020	AU 1998-67718	19980324
AU 727339	B2	20001207		
BR 9807892	A	20000222	BR 1998-7892	19980324
EP 980203	A1	20000223	EP 1998-913086	19980324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2000119188	A2	20000425	JP 1999-315917	19980324
NO 9904639	A	19991124	NO 1999-4639	19990924
PRAI US 1997-824041	A	19970326		
JP 1998-545926	A3	19980324		
WO 1998-US5792	W	19980324		

L7 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1998:293427 CAPLUS
DN 129:8597
TI Embedding and encapsulation of controlled release particles
IN Van Lengerich, Bernhard H.
PA Van Lengerich, Bernhard H., USA
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9818610	A1	19980507	WO 1997-US18984	19971027
W: AU, CA, JP, NO, PL, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9749915	A1	19980522	AU 1997-49915	19971027
EP 935523	A1	19990818	EP 1997-912825	19971027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NO 9902036	A	19990428	NO 1999-2036	19990428
PRAI US 1996-29038		19961028		
US 1997-52717		19970716		
WO 1997-US18984		19971027		

L7 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1998:17976 CAPLUS
DN 128:61798
TI Preparation of epoxide peptidomimetics as irreversible **HIV** protease inhibitors
IN Yoon, Heungsik; Choy, Nakyen; Kim, Sung Chun; Choi, Ho Il; Son, Young Chan; Park, Chi Hyo; Moon, Kwang-yul; Jung, Wonhee; Kim, Chung Ryeol; Lee, Chang Sun; Koh, Jong Sung; Kim, Sang Soo
PA LG Chemical Ltd., S. Korea
SO U.S., 50 pp. Cont.-in-part of U.S. Ser. No. 341,352, abandoned.

CODEN: USXXAM
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5696134	A	19971209	US 1995-473877	19950607
	US 5587388	A	19961224	US 1993-159382	19931130
	KR 125117	B1	19971205	KR 1994-13423	19940615
	US 5773468	A	19980630	US 1995-572402	19951214
	US 5744621	A	19980428	US 1996-667888	19960620
	US 5763631	A	19980609	US 1996-667133	19960620
PRAI	US 1993-159382	A2	19931130		
	KR 1994-13423	A	19940615		
	US 1994-341352	B2	19941117		
	KR 1992-23088	A	19921202		
	KR 1992-23089	A	19921202		
	KR 1993-10811	A	19930614		
	KR 1993-21298	A	19931014		
	KR 1993-21299	A	19931014		
	KR 1993-21300	A	19931014		
	US 1995-473877	A2	19950607		
	KR 1995-37292	A	19951026		

OS MARPAT 128:61798

L7 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1997:606368 CAPLUS
DN 127:272289
TI Apoptotic DNA fragmentation, and its in vitro prevention by nicotinamide, in lymphocytes from **HIV**-1-seropositive patients and in **HIV**-1-infected MT-4 cells
AU Savarino, A.; Martini, C.; Orofino, G. C.; Cantamessa, C.; Castelli, L.; Pich, P. G.; Sinicco, A.; Pugliese, A.
CS Department of Medical and Surgical Sciences, Section of Infectious Diseases, University of Turin, Italy
SO Cell Biochem. Funct. (1997), 15(3), 171-179
CODEN: CBFUDH; ISSN: 0263-6484
PB Wiley
DT Journal
LA English

L7 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1997:132760 CAPLUS
DN 126:144550
TI **HIV**-protease inhibitors
IN Kato, Ryohei; Mimoto, Tsutomu; Fukazawa, Tominaga; Morohashi, Naoko; Kiso, Yoshiaki
PA Japan Energy Corporation, Japan
SO Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 751145	A2	19970102	EP 1996-304764	19960628
	EP 751145	A3	19971008		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2179935	AA	19961231	CA 1996-2179935	19960626
	JP 10025242	A2	19980127	JP 1996-185631	19960626
	ZA 9605472	A	19970127	ZA 1996-5472	19960627
	NO 9602748	A	19970102	NO 1996-2748	19960628

AU 9656285 A1 19970206 AU 1996-56285 19960628
AU 705193 B2 19990520
PRAI JP 1995-188151 A 19950630
JP 1996-140678 A 19960510
OS MARPAT 126:144550

L7 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1997:79334 CAPLUS
DN 126:143042
TI Investigation of the potential role of membrane CD38 in protection against
cell death induced by **HIV**-1
AU Savarino, A.; Pugliese, A.; Martini, C.; Pich, P.G.; Pescarmona, G.P.; Malavasi, F.
CS Department of Medical and Surgical Sciences, University of Torino, Turin, Italy
SO J. Biol. Regul. Homeostatic Agents (1996), 10(1), 13-18
CODEN: JBRAER; ISSN: 0393-974X
PB Wichtig
DT Journal
LA English

L7 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1996:515414 CAPLUS
DN 125:276411
TI Synthesis and antiviral activity of N-4'-dihydropyridinyl and dihydroquinolinylcarbonyl-2-hydroxymethyl-5-[cytosin-1'-yl]-1,3-oxathiolane derivatives against human immunodeficiency virus and duck hepatitis B virus
AU Camplo, M.; Charvey-Faury, A. S.; Borel, C.; Turin, F.; Hantz, O.; Traubaud, C.; Niddam, V.; Mourier, N.; Graciet, J. C.; et al.
CS Labroatoire de Chimie Biolmoleculaire, Faculte des Sciences de Luminy, Marseille, 13288, Fr.
SO Eur. J. Med. Chem. (1996), 31(7-8), 539-546
CODEN: EJMCA5; ISSN: 0223-5234
DT Journal
LA English

L7 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1996:171803 CAPLUS
DN 124:233139
TI Preparation of sulfonylamino acid amides containing cis-epoxide as irreversible **HIV** protease inhibitors
IN Yoon, Heungsik; Choy, Nakyen; Kim, Sung Chun; Choi, Ho II; Son, Young Chan; Park, Chi Hyo; Moon, Kwang-Yul; Jung, Wonhee; Kim, Chung Ryeol; et al.
PA IG Chemical Ltd., S. Korea
SO Eur. Pat. Appl., 58 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 7

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 687675	A2	19951220	EP 1995-108908	19950609
EP 687675	A3	19960306		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
KR 125117	B1	19971205	KR 1994-13423	19940615
JP 08193077	A2	19960730	JP 1995-172733	19950615
JP 2987313	B2	19991206		
PRAI KR 1994-13423	A	19940615		

OS MARPAT 124:233139

L7 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1995:958459 CAPLUS
DN 124:7065
TI Biochemically active agents for chemical catalysis and cell receptor activation
IN Kossovsky, Nir; Sponsler, Edward; Gelman, Andrew; Rajguru, Samir
PA The Regents of the University of California, USA
SO U.S., 13 pp. Cont.-in-part of U.S. 5,334,394.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5460830	A	19951024	US 1993-145870	19931101
	US 5219577	A	19930615	US 1990-542255	19900622
	US 5178882	A	19930112	US 1991-690601	19910424
	JP 05255111	A2	19931005	JP 1991-178805	19910624
	JP 2932406	B2	19990809		
	US 5334394	A	19940802	US 1993-199	19930104
	US 5462750	A	19951031	US 1994-225100	19940408
	WO 9512392	A1	19950511	WO 1994-US12515	19941031
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2174244	AA	19950511	CA 1994-2174244	19941031
	EP 726767	A1	19960821	EP 1995-901094	19941031
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09504790	T2	19970513	JP 1994-513349	19941031

PRAI US 1990-542255 19900622
US 1991-690601 19910424
US 1993-199 19930104
US 1993-986 19930106
US 1993-145870 19931101
US 1993-146536 19931101
US 1993-147751 19931104
WO 1994-US12515 19941031

L7 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1995:871984 CAPLUS
DN 123:279761
TI Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
IN Vazquez, Michael L.; Mueller, Richard A.; Talley, John J.; Getman, Daniel P.; Decrescenzo, Gary A.; Freskos, John N.; Bertenshaw, Deborah E.; Heintz, Robert M.
PA Searle, G. D., and Co., USA; Monsanto Co.
SO PCT Int. Appl., 255 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9506030	A1	19950302	WO 1994-US9139	19940823
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, US, UZ, VN				
	RW: KE, MW, SD, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5843946	A	19981201	US 1993-110911	19930824

	US 6060476	A	20000509	US 1994-204827	19940302
	AU 9476697	A1	19950321	AU 1994-76697	19940823
	EP 715618	A1	19960612	EP 1994-927162	19940823
	EP 715618	B1	19981216		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 6046190	A	20000404	US 1996-586866	19960124
PRAI	US 1993-110911	A	19930824		
	US 1994-204827	A	19940302		
	US 1992-934984	B2	19920825		
	WO 1993-US7814	A2	19930824		
	US 1994-204872	B2	19940302		
	WO 1994-US9139	W	19940823		

OS MARPAT 123:279761

L7 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1995:701735 CAPLUS
DN 123:112727
TI Preparation of dipeptide derivatives of 5-amino-4-hydroxyhexanoic acid as **HIV** protease inhibitors.
IN Bold, Guido; Lang, Marc; Faessler, Alexander; Capraro, Hans-Georg; Bhagwat, Shripad
PA Ciba-Geigy A.-G., Switz.
SO Eur. Pat. Appl., 116 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 618222	A2	19941005	EP 1994-810133	19940302
	EP 618222	A3	19970102		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AU 9457588	A1	19940915	AU 1994-57588	19940304
	AU 678202	B2	19970522		
	FI 9401064	A	19940912	FI 1994-1064	19940307
	CA 2118661	AA	19940912	CA 1994-2118661	19940309
	NO 9400853	A	19940912	NO 1994-853	19940310
	ZA 9401668	A	19940913	ZA 1994-1668	19940310
	HU 67089	A2	19950130	HU 1994-720	19940310
	CN 1112125	A	19951122	CN 1994-104099	19940310
	JP 07316191	A2	19951205	JP 1994-67908	19940311
PRAI	CH 1993-772		19930311		

OS MARPAT 123:112727

L7 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1995:673568 CAPLUS
DN 123:109959
TI **HIV** infection decreases intracellular nicotinamide adenine dinucleotide [NAD]
AU Murray, Michael F.; Nghiem, Michael; Srinivasan, Alagarsamy
CS Dep. Med., Univ. PA Sch. Med., Philadelphia, PA, USA
SO Biochem. Biophys. Res. Commun. (1995), 212(1), 126-31
CODEN: BBRCA9; ISSN: 0006-291X
DT Journal
LA English

L7 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1995:590755 CAPLUS
DN 123:357
TI Nicotinamide inhibits **HIV**-1 in both acute and chronic in vitro infection
AU Murray, Michael F.; Srinivasan, Alagarsamy

CS Department of Medicine, University of PA School of Medicine, Philadelphia,
Panama
SO Biochem. Biophys. Res. Commun. (1995), 210(3), 954-9
CODEN: BBRCA9; ISSN: 0006-291X
DT Journal
LA English

L7 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1995:556533 CAPLUS
DN 123:143841
TI Synthesis and antiviral evaluation of fluorinated dipyridodiazepinones and
dipyridodiazepines (nevirapine derivatives)
AU Boyode, B. P.; Sinet, M.; Barese, A.; Forestier-Roux, M.-A.; Condom, R.; Ayi, I. A.; Kirn, A.; Moog, C.; Guedj, R.
CS Faculte Sciences, Universite Nice-Sophia Antipolis, Nice, F-06108, Fr.
SO Antiviral Chem. Chemother. (1995), 6(3), 162-8
CODEN: ACCHEH; ISSN: 0956-3202
DT Journal
LA English

L7 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1993:650508 CAPLUS
DN 119:250508
TI Preparation of 5-amino-4-hydroxyhexanoic acid derivative containing peptides as **HIV** protease inhibitors
IN Lang, Marc; Bold, Guido; Faessler, Alexander; Schneider, Peter; Van Hoogesvest, Peter
PA Ciba-Geigy A.-G., Switz.
SO Eur. Pat. Appl., 79 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 532466	A2	19930317	EP 1992-810678	19920903
	EP 532466	A3	19930616		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 05230095	A2	19930907	JP 1992-238424	19920907
	CA 2077948	AA	19930313	CA 1992-2077948	19920910
	AU 9222889	A1	19930318	AU 1992-22889	19920910
	AU 661018	B2	19950713		
	IL 103126	A1	19970930	IL 1992-103126	19920910
	NO 9203533	A	19930315	NO 1992-3533	19920911
	HU 63632	A2	19930928	HU 1992-2925	19920911
	ZA 9206938	A	19940311	ZA 1992-6938	19920911
	PL 169969	B1	19960930	PL 1992-295905	19920911
	RU 2067585	C1	19961010	RU 1992-5052915	19920911
	CN 1089269	A	19940713	CN 1993-100044	19930104
PRAI	CH 1991-2689		19910912		
	CH 1992-980		19920327		
	CH 1992-2007		19920625		

OS MARPAT 119:250508

L7 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1993:22632 CAPLUS
DN 118:22632
TI Preparation of peptide analogs for treatment of acquired immunodeficiency syndrome
IN Yabe, Yuichiro; Sakurai, Mitsuya; Higashida, Susumu; Komai, Tomoaki;

Nishigaki, Takashi; Handa, Hiroshi
PA Sankyo Co., Ltd., Japan
SO Eur. Pat. Appl., 96 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 498680	A1	19920812	EP 1992-301100	19920210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
JP 05078311	A2	19930330	JP 1992-21385	19920206
JP 2500034	B2	19960529		
CA 2060844	AA	19920809	CA 1992-2060844	19920207
AU 9210812	A1	19920813	AU 1992-10812	19920207
AU 647239	B2	19940317		
HU 60282	A2	19920828	HU 1992-392	19920207
ZA 9200913	A	19930506	ZA 1992-913	19920207
IL 100899	A1	19970610	IL 1992-100899	19920207
RU 2120447	C1	19981020	RU 1992-5011192	19920207
CN 1064683	A	19920923	CN 1992-101909	19920208
CN 1039321	B	19980729		
PRAI JP 1991-17341		19910208		

OS MARPAT 118:22632

L7 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1992:612977 CAPLUS
DN 117:212977
TI Preparation of retroviral protease inhibitors derived from 3-chloro-2-chloromethyl-1-propene
IN Babine, Robert E.; Zhang, Nan; Schow, Steven R.; Jurgens, Alex Roger
PA American Cyanamid Co., USA
SO Eur. Pat. Appl., 71 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 492136	A2	19920701	EP 1991-119897	19911122
EP 492136	A3	19930526		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 04334349	A2	19921120	JP 1991-353289	19911217
CA 2057972	AA	19920621	CA 1991-2057972	19911218
FI 9106022	A	19920621	FI 1991-6022	19911219
NO 9105030	A	19920622	NO 1991-5030	19911219
HU 59655	A2	19920629	HU 1991-4036	19911219
AU 9189941	A1	19920709	AU 1991-89941	19911219
ZA 9110016	A	19920930	ZA 1991-10016	19911219
CN 1062536	A	19920708	CN 1991-111849	19911220
PRAI US 1990-630915		19901220		

OS MARPAT 117:212977

L7 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1991:622844 CAPLUS
DN 115:222844
TI Inhibitors of ADP-ribosylation as antiviral drugs: experimental study on the model of **HIV** infection
AU Krasil'nikov, I. I.; Kalnina, L. B.; Korneeva, M. N.; Nosik, D. N.; Zlobin, A. Yu.; Vladimirov, V. G.; L'vov, D. K.
CS Inst. Virusol. im. Ivanovskogo, Moscow, USSR
SO Vopr. Virusol. (1991), 36(3), 216-18
CODEN: VVIRAT; ISSN: 0507-4088

DT Journal
LA Russian

L7 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1991:95145 CAPLUS
DN 114:95145
TI AZT analogs for treatment of **retrovirus** infections
IN Agrawall, Kirshna
PA Tulane Educational Fund, Inc., USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9004969	A1	19900517	WO 1989-US4860	19891030
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 5026688	A	19910625	US 1988-265201	19881031
CA 2001899	AA	19900430	CA 1989-2001899	19891031
PRAI US 1988-265201		19881031		

OS MARPAT 114:95145

L7 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1990:610545 CAPLUS
DN 113:210545
TI Micronutrient status and human immunodeficiency virus (**HIV**) infection
AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp, Francis; Bruening, Kay; Louria, Donald
CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
SO Ann. N. Y. Acad. Sci. (1990), 587(Micronutr. Immune Funct./Cytokines Metab.), 189-95
CODEN: ANYAA9; ISSN: 0077-8923
DT Journal
LA English

L7 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1990:497961 CAPLUS
DN 113:97961
TI Brain targeting of anti-**HIV** nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine
AU Chu, C. K.; Bhadti, V. S.; Doshi, K. J.; Etse, J. T.; Gallo, J. M.; Boudinot, F. D.; Schinazi, R. F.
CS Coll. Pharm., Univ. Georgia, Athens, GA, 30602, USA
SO J. Med. Chem. (1990), 33(8), 2188-92
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 113:97961

L7 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1990:198959 CAPLUS
DN 112:198959
TI Synthesis and biological evaluation of prodrugs of zidovudine
AU Aggarwal, Sunil K.; Gogu, Sudhir R.; Rangan, S. R. S.; Agrawal, Krishna C.
CS Sch. Med., Tulane Univ., New Orleans, LA, 70112, USA
SO J. Med. Chem. (1990), 33(5), 1505-10
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English

OS .CASREACT 112:198959

L7 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1990:151841 CAPLUS
DN 112:151841
TI Preparation of glycerophosphate derivatives as animal virucides
IN Shenfeld, Avner
PA Scienscope International N. V., Neth.
SO Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 316117	A1	19890517	EP 1988-310391	19881104
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 8904314	A1	19890518	WO 1988-NL48	19881102
	W: AU, BB, BG, BR, DK, FI, HU, JP, KP, KR, LK, MC, MG, MW, NL, NO, RO, SD, SU				
	RW: BJ, CF, CG, CM, GA, ML, MR, SN, TD, TG				
	AU 8826199	A1	19890601	AU 1988-26199	19881102
	JP 02502096	T2	19900712	JP 1988-508750	19881102
	FI 8903279	A	19890705	FI 1989-3279	19890705
PRAI	IL 1987-84387		19871106		
	WO 1988-N				

L48 19881102
OS MARPAT 112:151841

=> s l5 andl l6

MISSING OPERATOR L5 ANDL
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l5 and l6

L8 9 L5 AND L6

=> d l8 109

9 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):9

L8 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2001 ACS
AN 1990:151841 CAPLUS
DN 112:151841
TI Preparation of glycerophosphate derivatives as animal virucides
IN Shenfeld, Avner
PA Scienscope International N. V., Neth.
SO Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 316117	A1	19890517	EP 1988-310391	19881104
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				

```
     .WO 8904314        A1   19890518       WO 1988-NL48     19881102
         W:  AU, BB, BG, BR, DK, FI, HU, JP, KP, KR, LK, MC, MG, MW, NL, NO,
             RO, SD, SU
         RW: BJ, CF, CG, CM, GA, ML, MR, SN, TD, TG
     AU 8826199         A1   19890601       AU 1988-26199    19881102
     JP 02502096        T2   19900712       JP 1988-508750   19881102
     FI 8903279         A    19890705       FI 1989-3279     19890705
PRAI IL 1987-84387           19871106
     WO 1988-N
L48           19881102
OS   MARPAT 112:151841


=> d 17 30 29 27 26 20 12 10 8 all


L7   ANSWER 30 OF 30  CAPLUS  COPYRIGHT 2001 ACS
AN   1990:151841  CAPLUS
DN   112:151841
TI   Preparation of glycerophosphate derivatives as animal virucides
IN   Shenfeld, Avner
PA   Scienscope International N. V., Neth.
SO   Eur. Pat. Appl., 22 pp.
     CODEN: EPXXDW
DT   Patent
LA   English
IC   ICM  C07F009-10
     ICS  C07F009-09; C07F009-58; A61K031-66
CC   1-5 (Pharmacology)
     Section cross-reference(s): 27
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   EP 316117          A1   19890517       EP 1988-310391   19881104
         R:  AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE
     WO 8904314         A1   19890518       WO 1988-NL48     19881102
         W:  AU, BB, BG, BR, DK, FI, HU, JP, KP, KR, LK, MC, MG, MW, NL, NO,
             RO, SD, SU
         RW: BJ, CF, CG, CM, GA, ML, MR, SN, TD, TG
     AU 8826199         A1   19890601       AU 1988-26199    19881102
     JP 02502096        T2   19900712       JP 1988-508750   19881102
     FI 8903279         A    19890705       FI 1989-3279     19890705
PRAI IL 1987-84387           19871106
     WO 1988-N
L48           19881102
OS   MARPAT 112:151841
AB   The acylglycerophosphate esters R1OCH2CH(OR2)CH2OP(O)(O-)GAzR3 [R1, R2 =
     H, fatty acyl; A = CH2, polymethylene, oxapolymethylene,
     thiapolymethylene, etc. R3 = (un)substituted Ph or pyridinium, etc.; G =
     O, S; Z = 0, 1-18] are prepd. as virucides, suitable for treating human
     immunodeficiency virus (HIV) infections.  2-Hydroxyethyl-1-
     nicotinamide chloride (prepn. given) was transphosphatidylated
     enzymically, by the method of Eibel and Kovatchev (1981), to give
     phosphatidyl-2-hydroxyethyl-1-nicotinamide (I).  I (20 .mu.g/mL) totally
     controlled HIV, in vitro, as shown by the method of Moore, et
     al. (1978).
ST   virucide animal phospholipid; glycerophosphate deriv prepn AIDS drug
IT   Phosphatidylethanolamines
     RL: RCT (Reactant)
        (acetylation of)
IT   Phospholipids, biological studies
     RL: BAC (Biological activity or effector, except adverse); BIOL
     (Biological study)
```

(virucides, animal)
IT Immunodeficiency
(acquired immune deficiency syndrome, treatment of, with reaction products of acylglycerophosphates with alcs. and thiols)
IT Phosphatidic acids
RL: SPN (Synthetic preparation); PREP (Preparation)
(esters, prepn. of, as animal virucides)
IT Virucides and Virustats
(medical, reaction products of acid glycerophosphates with alcs. or thiols)
IT Phosphatidylethanolamines
RL: SPN (Synthetic preparation); PREP (Preparation)
(reaction products, with acetic anhydride, prepn. of, as animal virucide)
IT **98-92-0**, Nicotinamide
RL: BIOL (Biological study)
(condensation of, with chloroethanol)
IT 107-07-3, 2-Chloroethanol, biological studies
RL: BIOL (Biological study)
(condensation of, with nicotinamide)
IT 126235-31-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and transphosphatidylation of)
IT 58-27-5DP, reaction products with phosphatidylethanolamines 100-51-6DP, Benzenemethanol, reaction products with phosphatidic acids 108-24-7DP, reaction products with phosphatidylethanolamines 141-79-7DP, reaction products with phosphatidylethanolamines 126235-31-2DP, reaction products
with phosphatidic acids
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as animal virucide)
IT 58-27-5, Menadione
RL: RCT (Reactant)
(reaction of, with phosphatidylethanolamine)

L7 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1990:198959 CAPLUS
DN 112:198959
TI Synthesis and biological evaluation of prodrugs of zidovudine
AU Aggarwal, Sunil K.; Gogu, Sudhir R.; Rangan, S. R. S.; Agrawal, Krishna C.
CS Sch. Med., Tulane Univ., New Orleans, LA, 70112, USA
SO J. Med. Chem. (1990), 33(5), 1505-10
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
CC 33-9 (Carbohydrates)
Section cross-reference(s): 1
OS CASREACT 112:198959
GI



I



I

AB A series of prodrugs of zidovudine (AZT) was synthesized in an effort to enhance the uptake of the prodrugs by the **HIV**-1 infected cells and to increase the plasma half-life of AZT. The 5'-OH function of AZT was esterified with various acids in the presence of DCC and 4-(dimethylamino)pyridine (DMAP). The prodrug moieties included (a) morpholine and N-phenylpiperazine-1-acetic acid, (b) 1,4-dihydro-1-methyl-3-nicotinic acid, (c) retinoic acid, and (d) certain amino acids. The anti-**HIV**-1 activity of the esters was detd. in peripheral blood lymhpocytes. The IC50 for AZT in this system was 0.12 .mu.M whereas for prodrugs it ranged from 0.05 to 0.2 .mu.M. The prodrugs were generally less cytotoxic than AZT except the retinoic acid ester. In vitro hydrolysis of the various esters in human plasma indicated that these agents were relatively stable toward plasma esterases with t1/2 ranging from 10 to 240 min. Drug uptake studies in H9 cells with radiolabeled analogs demonstrated that the retinoic acid ester achieved approx. 4-fold higher intracellular concn. than [3H]AZT. However, dihydromethylpyridylcarbonyl ester (I) was the most active agent of this series and had a higher therapeutic index than AZT.

ST zidovudine prodrug prepn biolog evaluation; AZT acyl AIDS inhibitor; cytotoxicity zidovudine prodrug

IT Virucides and Virustats
(acyl zidovudines)

IT Immunodeficiency
(acquired immune deficiency syndrome, inhibitors, acyl zidovudines as, prepn. of)

IT Pharmaceutical dosage forms
(prodrugs, acyl zidovudines)

IT **59-67-6**, 3-Pyridinecarboxylic acid, reactions 302-79-4, Retinoic acid 2483-46-7 3235-69-6, 4-Morpholineacetic acid 3978-80-1 13139-16-7 13734-34-4 13734-38-8 24277-39-2 119378-70-0
RL: RCT (Reactant)
(acylation by, of zidovudine)

IT 30516-87-1, Zidovudine
RL: RCT (Reactant)
(acylation of, by retinoic and amino acids)

IT 125780-78-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and attempted debutoxycarbonylation of)

IT 116333-41-6P 116333-43-8P 125762-96-1P 125762-97-2P 125780-80-5P 125780-82-7P 125780-84-9P 125780-86-1P 125780-96-3P 125780-97-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and bioactivity of)

IT 125780-75-8P 125780-76-9P 125780-77-0P 125780-85-0P 125780-98-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and debutoxycarbonylation of)

L7 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1990:610545 CAPLUS

DN 113:210545
TI Micronutrient status and human immunodeficiency virus (**HIV**) infection
AU Bogden, John D.; Baker, Herman; Frank, Oscar; Perez, George; Kemp, Francis; Bruening, Kay; Louria, Donald
CS New Jersey Med. Sch., Univ. Med. Dent., Newark, NJ, 07103-2757, USA
SO Ann. N. Y. Acad. Sci. (1990), 587(Micronutr. Immune Funct./Cytokines Metab.), 189-95
CODEN: ANYAA9; ISSN: 0077-8923
DT Journal
LA English
CC 18-1 (Animal Nutrition)
Section cross-reference(s): 14, 15
AB Humans with **HIV** infections generally showed .gtoreq.1 abnormally low level of plasma micronutrients (e.g. minerals, vitamins). Abnormally high levels of some micronutrients were also found, but these were attributed to the ingestion of high supplement amts.
ST micronutrient nutrition human immunodeficiency virus infection; **HIV** infection diet micronutrient
IT Carotenes and Carotenoids, biological studies
Trace elements, biological studies
Vitamins
RL: BIOL (Biological study)
(**HIV** virus infection in humans in relation to nutritional status of)
IT Virus, animal
(human immunodeficiency 1, humans infection by, micronutrient status in
relation to)
IT Nutrients
(micro-, **HIV** virus infection in humans in relation to nutritional status of)
IT 50-81-7, Vitamin C, biological studies 58-85-5, Biotin 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies **59-67-6**, Niacin, biological studies 62-49-7, Choline 68-19-9, Vitamin B12 79-83-4, Pantothenic acid 83-88-5, Riboflavin, biological studies 87-89-8, Inositol 541-15-1, Carnitine 1406-18-4, Vitamin E 7439-95-4, Magnesium, biological studies 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 8059-24-3, Vitamin B6 11103-57-4, Vitamin A 22150-76-1, Biopterin
RL: BIOL (Biological study)
(**HIV** virus infection in humans in relation to nutritional status of)

L7 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1991:95145 CAPLUS
DN 114:95145
TI AZT analogs for treatment of **retrovirus** infections
IN Agrawall, Kirshna
PA Tulane Educational Fund, Inc., USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-70
CC 1-5 (Pharmacology)
Section cross-reference(s): 33
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9004969	A1	19900517	WO 1989-US4860	19891030

RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE

	US 5026688	A	19910625	US 1988-265201	19881031
	CA 2001899	AA	19900430	CA 1989-2001899	19891031
PRAI	US 1988-265201		19881031		

OS MARPAT 114:95145
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB AZT analogs I (R = Q1, Q2, Q3; X = H, CO2H, C1-6 alkyl, PhCH2; Y = C1-6 alkyl, C6-10 aryl) are used for the treatment of retroviral infection. Thus, II (prepn. described) inhibited human immunodeficiency virus 1 replication 99.1% in vitro at 0.5 .mu.M, vs. 82.0% for AZT. Toxicity data for II are also presented.

ST AZT analog **retrovirus** infection; human immunodeficiency virus AZT analog

IT Virucides and Virustats
(AZT analogs as, for retroviral infection)

IT Virus, animal
(human immunodeficiency 1, infection with, treatment of, AZT analogs for)

IT Virus, animal
(retro-, infection with, treatment of, AZT analogs for)

IT **59-67-6**, 3-Pyridinecarboxylic acid, biological studies
RL: BIOL (Biological study)
(condensation of, with AZT)

IT 30516-87-1
RL: BIOL (Biological study)
(condensation of, with nicotinic acid)

IT 116333-41-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and human immunodeficiency virus inhibitory action of)

IT 116333-43-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and quaternization of, in AZT analog prepn.)

IT 132186-39-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

IT 116333-42-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, in AZT analog prepn.)

IT 30516-87-1D, analogs 116333-41-6 116333-43-8 125762-96-1 125780-79-2 125780-81-6 125780-97-4 132186-35-7 132186-36-8 132186-37-9 132186-38-0
RL: BIOL (Biological study)
(**retrovirus** infection treatment with)

L7 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1995:590755 CAPLUS
DN 123:357
TI Nicotinamide inhibits **HIV**-1 in both acute and chronic in vitro infection
AU Murray, Michael F.; Srinivasan, Alagarsamy
CS Department of Medicine, University of PA School of Medicine, Philadelphia, Panama
SO Biochem. Biophys. Res. Commun. (1995), 210(3), 954-9
CODEN: BBRCA9; ISSN: 0006-291X
DT Journal
LA English

CC 1-5 (Pharmacology)
AB **HIV**-1 infected patients can manifest a no. of poorly understood conditions including dermatitis, dementia, and diarrhea. These conditions
are in some ways suggestive of pellagra, the syndrome assocd. with niacin depletion. We demonstrate here that nicotinamide, the amide form of niacin, inhibits **HIV**-1 infection in cell culture. Neither nicotinic acid which is the alternative form of niacin, nor thiamine (another B complex vitamin), shows a similar degree of inhibition in tissue culture. This inhibition occurs in both primary cells and in established cell lines. In vitro models of acute and chronic **HIV** infection are demonstrated here to be inhibited by nicotinamide in a dose dependent manner when added in millimolar concns.
ST nicotinamide HIV1 infection inhibition
IT Virucides and Virustats
(nicotinamide inhibition of **HIV**-1 in acute and chronic in vitro infection)
IT Virus, animal
(human immunodeficiency 1, nicotinamide inhibition of **HIV**-1 in acute and chronic in vitro infection)
IT **98-92-0**, Nicotinamide
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of **HIV**-1 in acute and chronic in vitro infection by)
IT 59-43-8, Thiamine, biological studies **59-67-6**, Nicotinic acid, biological studies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nicotinamide inhibition of **HIV**-1 in acute and chronic in vitro infection comparison with)

L7 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1997:132760 CAPLUS
DN 126:144550
TI **HIV**-protease inhibitors
IN Kato, Ryohei; Mimoto, Tsutomu; Fukazawa, Tominaga; Morohashi, Naoko; Kiso, Yoshiaki
PA Japan Energy Corporation, Japan
SO Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C07K005-02
ICS C07D207-16; C07D263-06; C07D277-06; A61K031-40; A61K031-42; A61K031-425
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 15
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 751145	A2	19970102	EP 1996-304764	19960628
	EP 751145	A3	19971008		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2179935	AA	19961231	CA 1996-2179935	19960626
	JP 10025242	A2	19980127	JP 1996-185631	19960626
	ZA 9605472	A	19970127	ZA 1996-5472	19960627
	NO 9602748	A	19970102	NO 1996-2748	19960628
	AU 9656285	A1	19970206	AU 1996-56285	19960628
	AU 705193	B2	19990520		
PRAI	JP 1995-188151	A	19950630		
	JP 1996-140678	A	19960510		

OS .MARPAT 126:144550
GI



I

AB Dipeptides I (X = CH2, CHCl, O, S, SO2; R = 5- or 6-membered monocyclic hydrocarbon or heterocyclic group; R1 = alkyl, monocyclic hydrocarbon group; R2, R3 = H, alkyl) were prepd. as **HIV**-protease inhibitors. Thus, treatment of a suspension of (R)-[(2S,3S)-3-amino-2-hydroxy-4-phenylbutanoyl]-1,3-thiazolidine-4-N'-tert-butylcarboxamide, (2S,3S)-H-AHPBA-Thz-NH-tBu, and benzoic acid in DMF with EDC.HCl and HOBt-H2O for 14 h at room temp. afforded benzoyl deriv. I (X = S, R = Ph, R1 = t-Bu, R2 = R3 = H). The latter compd. showed 52.0 % **HIV** protease inhibitor activity at a concn. of 5 .mu.M.

ST heterocyclyl dipeptide prepn **HIV** protease inhibitor

IT Human immunodeficiency virus
(prepn. of **HIV**-protease inhibitors)

IT Peptides, preparation
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of **HIV**-protease inhibitors)

IT 183107-57-5P 183107-74-6P 186537-64-4P 186537-65-5P 186537-69-9P
186537-70-2P 186537-76-8P 186537-84-8P 186537-85-9P 186537-87-1P
186537-88-2P 186537-89-3P 186537-90-6P 186537-91-7P 186537-92-8P
186537-93-9P 186537-94-0P 186537-95-1P 186537-96-2P 186537-97-3P
186537-98-4P 186537-99-5P 186538-00-1P 186538-01-2P 186538-02-3P
186538-03-4P 186538-04-5P 186538-05-6P 186538-06-7P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of **HIV**-protease inhibitors)

IT 144114-21-6, Retropepsin
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(prepn. of **HIV**-protease inhibitors)

IT 55-22-1, Isonicotinic acid, reactions **59-67-6**, Nicotinic acid, reactions 69-72-7, Salicylic acid, reactions 85-44-9, 1,3-Isobenzofurandione 88-13-1, 3-Thiophenecarboxylic acid 88-14-2, 2-Furancarboxylic acid 89-93-0, 2-Methylbenzylamine 98-98-6, Picolinic acid 99-04-7, m-Toluic acid 99-06-9, m-Hydroxybenzoic acid, reactions 99-10-5 99-94-5, p-Toluic acid 99-96-7, reactions 118-90-1, o-Toluic acid 121-91-5, 1,3-Benzenedicarboxylic acid, reactions 488-93-7, 3-Furancarboxylic acid 527-72-0, 2-Thiophenecarboxylic acid 548-93-6, 2-Amino-3-hydroxybenzoic acid 603-79-2, 2,3-Dimethylbenzoic acid 603-80-5, 3-Hydroxy-2-methylbenzoic acid 1679-64-7, Monomethyl terephthalate 28169-46-2, 2-Methyl-3,5-dinitrobenzoic acid 51077-16-8 52130-17-3, 3-Amino-2-methylbenzoic acid 66493-39-8 68790-38-5 111331-82-9 116661-86-0 147318-83-0 153380-43-9 158941-63-0 161979-36-8 166383-59-1 168899-32-9, 2-Ethyl-3-hydroxybenzoic acid 168899-38-5, 3-Hydroxy-2-propylbenzoic acid 177355-09-8 184955-18-8 186538-11-4 186538-15-8 186538-16-9 186538-17-0 186538-18-1 186538-19-2 186538-20-5
RL: RCT (Reactant)

(prepn. of **HIV**-protease inhibitors)

IT 143935-42-6P 186538-07-8P 186538-08-9P 186538-09-0P 186538-10-3P
186538-12-5P 186538-14-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of **HIV**-protease inhibitors)

IT 186537-75-7P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of **HIV**-protease inhibitors)

IT 186537-66-6P 186537-67-7P 186537-68-8P 186537-71-3P 186537-72-4P
186537-73-5P 186537-74-6P 186537-77-9P 186537-78-0P 186537-79-1P
186537-80-4P 186537-81-5P 186537-82-6P 186537-83-7P 186537-86-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of **HIV**-protease inhibitors)

L7 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1998:17976 CAPLUS
DN 128:61798
TI Preparation of epoxide peptidomimetics as irreversible **HIV** protease inhibitors
IN Yoon, Heungsik; Choy, Nakyen; Kim, Sung Chun; Choi, Ho Il; Son, Young Chan; Park, Chi Hyo; Moon, Kwang-yul; Jung, Wonhee; Kim, Chung Ryeol; Lee,
Chang Sun; Koh, Jong Sung; Kim, Sang Soo
PA LG Chemical Ltd., S. Korea
SO U.S., 50 pp. Cont.-in-part of U.S. Ser. No. 341,352, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-44
ICS A61K031-47
NCL 514314000
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 63
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5696134	A	19971209	US 1995-473877	19950607
	US 5587388	A	19961224	US 1993-159382	19931130
	KR 125117	B1	19971205	KR 1994-13423	19940615
	US 5773468	A	19980630	US 1995-572402	19951214
	US 5744621	A	19980428	US 1996-667888	19960620
	US 5763631	A	19980609	US 1996-667133	19960620
PRAI	US 1993-159382	A2	19931130		
	KR 1994-13423	A	19940615		
	US 1994-341352	B2	19941117		
	KR 1992-23088	A	19921202		
	KR 1992-23089	A	19921202		
	KR 1993-10811	A	19930614		
	KR 1993-21298	A	19931014		
	KR 1993-21299	A	19931014		
	KR 1993-21300	A	19931014		
	US 1995-473877	A2	19950607		
	KR 1995-37292	A	19951026		

OS MARPAT 128:61798
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

..AB .Novel cis-epoxide compds. I [R1, R2 = independently H, alkyl; R3 = aryl or alkyl (un)substituted with arom., C3-8 cycloalkyl; R4 = H, C1-4 alkyl; n = 0-2; X = CO, COCO, S(O), SO2, CS; Y = O, CH2, NH, NMe; m = 0, 1; R5 = heterocycle; straight, branched, or cyclic C1-8 alkyl; alkyl substituted with heterocycle or cycloalkyl; straight, branched, or cyclic C1-8 alkoxy; aryl-substituted alkoxy; NR6R7; R6 = straight or branched C1-8 alkyl, cycloalkyl, alkyl substituted with cycloalkyl; R7 = H, alkyl; Z = O, NH, NMe; R8, R9 = independently alkyl (un)substituted with arom. hydrocarbon or cycloalkyl; C3-8 cycloalkyl; arom.] are useful for treating or preventing diseases caused by **HIV** infection. The novel **HIV** protease inhibitors I have specific structures to form stable bonding with the enzyme active site, which entails a highly enhanced irreversible inhibition against **HIV** protease. Thus deprotection and peptide coupling of olefin II (prepd. in 4 steps from protected L-phenylalaninal and (S)-2-amino-3-methyl-1-phenylbutane) with penicillamine-derived sulfone III (prepd. in 3 steps from L-penicillamine), followed by epoxidn. with mCPBA gave title epoxide deriv. IV. IV showed irreversible inactivation of **HIV**-1 protease, with a stoichiometric ratio of inhibitor to enzyme of 1:1. IV also showed antiviral activity against **HIV**-1 with IC50 = 1 nM.

ST epoxide peptidomimetic prepn **HIV** protease inhibitor; virucide **HIV** epoxide peptidomimetic prepn; AIDS treatment epoxide peptidomimetic prepn; immunomodulator epoxide peptidomimetic prepn

IT Peptidomimetics
(epoxide; prepn. of epoxide peptidomimetics as irreversible **HIV** protease inhibitors)

IT Epoxides
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptidomimetics; prepn. of epoxide peptidomimetics as irreversible **HIV** protease inhibitors)

IT Anti-AIDS drugs
Antiviral agents
Human immunodeficiency virus 1
Immunomodulators
(prepn. of epoxide peptidomimetics as irreversible **HIV** protease inhibitors)

IT 174562-29-9P 174562-30-2P 174562-31-3P 174562-32-4P 174562-33-5P
174562-34-6P 174562-35-7P 174562-36-8P 174562-37-9P 174562-38-0P
174562-39-1P 174562-40-4P 174562-41-5P 174562-42-6P 174562-43-7P
174562-44-8P 174562-45-9P 174562-46-0P 174562-47-1P 174562-48-2P
174562-49-3P 174562-50-6P 174562-51-7P 174562-52-8P 174562-53-9P
174562-54-0P 174562-55-1P 174562-56-2P 174562-57-3P 174562-58-4P
174562-59-5P 174562-60-8P 174562-61-9P 174562-62-0P 174562-63-1P
174562-65-3P 174562-66-4P 174562-67-5P 174562-68-6P 174562-69-7P
174562-70-0P 174562-71-1P 174562-72-2P 174562-73-3P 174562-74-4P
174562-75-5P 174562-76-6P 174562-77-7P 174562-78-8P 174562-79-9P
174562-80-2P 174562-81-3P 200262-27-7P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of epoxide peptidomimetics as irreversible **HIV** protease inhibitors)

IT 144114-21-6, Retropepsin
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(prepn. of epoxide peptidomimetics as irreversible **HIV** protease inhibitors)

IT **59-67-6**, 3-Pyridinecarboxylic acid, reactions 78-77-3, Isobutyl bromide 78-82-0, Isobutyronitrile 88-14-2, 2-Furancarboxylic acid

93-10-7, 2-Quinolinecarboxylic acid 96-41-3, Cyclopentanol 98-00-0, 2-Furanylmethanol 98-59-9, p-Toluenesulfonyl chloride 98-98-6, 2-Pyridinecarboxylic acid 100-46-9, Benzylamine, reactions 100-55-0, 3-Pyridylcarbinol 110-68-9, N-Methyl-N-butylamine 503-74-2, Isovaleric acid 527-72-0, 2-Thiophenecarboxylic acid 574-98-1, N-(2-Bromoethyl)phthalimide 586-95-8, 4-Pyridylcarbinol 586-98-1, 2-Pyridylcarbinol 603-35-0, Triphenylphosphine, reactions 617-89-0, 2-Furanylmethylamine 625-45-6, Methoxyacetic acid 1113-41-3, L-Penicillamine 2516-33-8, Cyclopropylmethanol 4083-57-2, 3-Amino-2,4-dimethylpentane 5163-20-2, N-Methyl-N-cyclopropylamine 6921-34-2, Benzylmagnesium chloride 6964-21-2, 3-Thiopheneacetic acid 7693-46-1, p-Nitrophenyl chloroformate 13734-34-4 23844-66-8 24939-24-0, p-Aminobenzenesulfonyl chloride 33445-07-7, Isopropoxyacetic acid 59830-60-3, N-Benzyloxycarbonyl-L-phenylalaninal 80866-93-9 96521-86-7 96928-87-9 111491-96-4 123617-80-1, 3-Furanacetic acid 136465-98-0
RL: RCT (Reactant)
(prepn. of epoxide peptidomimetics as irreversible **HIV** protease inhibitors)

IT 65273-64-5P 82894-53-9P 97589-56-5P 112898-22-3P 156641-79-1P 156641-81-5P 156641-83-7P 160742-44-9P 160742-45-0P 160742-70-1P 160742-71-2P 174562-82-4P 174562-83-5P 174562-84-6P 174562-85-7P 174562-86-8P 174562-88-0P 174562-89-1P 174562-90-4P 174562-91-5P 174562-92-6P 174562-94-8P 196515-98-7P 200262-28-8P 200262-29-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of epoxide peptidomimetics as irreversible **HIV** protease inhibitors)

IT 156715-06-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of epoxide peptidomimetics as irreversible **HIV** protease inhibitors)

L7 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2001 ACS
AN 1998:661494 CAPLUS
DN 129:298375
TI Antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases
IN Squires, Meryl
PA USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A01N033-12
ICS A61K031-14
CC 1-5 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9842188	A1	19981001	WO 1998-US5792	19980324
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9867718	A1	19981020	AU 1998-67718	19980324

AU 727339 B2 20001207
BR 9807892 A 20000222 BR 1998-7892 19980324
EP 980203 A1 20000223 EP 1998-913086 19980324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
JP 2000119188 A2 20000425 JP 1999-315917 19980324
NO 9904639 A 19991124 NO 1999-4639 19990924
PRAI US 1997-824041 A 19970326
JP 1998-545926 A3 19980324
WO 1998-US5792 W 19980324

AB An improved medical treatment and medicine is provided to quickly and safely resolve **HIV** and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial conc. comprising microbe inhibitors, phytochems. or isolates. Desirably, the effective medicine comprises a surfactant and an aq. carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochems., benzalkonium chloride, a sterile water soln., and folic acid.

ST phytochem nutrient antimicrobial **HIV**; Echinacea Commiphora phytochem surfactant antimicrobial **HIV**; folic acid phytochem antimicrobial **HIV**

IT Labia
Lip
Lymph node
Lymphatic system
Oral mucosa
T cell (lymphocyte)
(administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkylbenzyldimethyl, bromides; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Bacilli
(anaerobic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Topical drug delivery systems
(and systemic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Allium
Anise
Arctostaphylos
Artemisia
Baptisia
Calendula
Capsicum
Carum
Compositae (Asteraceae)
Coriandrum
Echinacea angustifolia
Echinacea atribactilus
Echinacea pallida
Echinacea purpurea
Echinacea vegetalis
Eucalyptus
Eugenia mytacea
Gentian (Gentiana)
Inula
Juniper (Juniperus)
Labiatae (Lamiaceae)
Meliosma

Mentha
Mentha aquatica hypeuria
Myroxylon
Origanum
Parthenium integrifolium
Plantago
Rosemary
Ruta
Sage (Salvia)
(antimicrobial isolates of; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Adenoviridae
Amphoteric surfactants
Antibacterial agents
Antimicrobial agents
Antiviral agents
Arbovirus
Arenavirus
Bird (Aves)
Cat (Felis catus)
Cationic surfactants
Cattle
Commiphora erythraea
Commiphora molmol
Commiphora myrrha
Coronavirus
Cytomegalovirus
Dog (Canis familiaris)
Drug delivery systems
Gums
Horse (Equus caballus)
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human parainfluenza virus
Influenza virus
Injections (drug delivery systems)
Livestock
Mycobacterium
Nasal drug delivery systems
Nonionic surfactants
Nutrients
Ophthalmic drug delivery systems
Papillomavirus
Picornaviridae
Rodent
Sexually transmitted diseases
Sheep
Staphylococcus
Streptococcus
Surfactants
Swine
Vaginal drug delivery systems
Zwitterionic surfactants
(antimicrobial prevention and treatment of human immunodeficiency virus
and other infectious diseases)

IT Amides, biological studies
Anthocyanins
Enzymes, biological studies
Fat-soluble vitamins

Natural products (pharmaceutical)
Polyacetylenes, biological studies
Polysaccharides, biological studies
Proteins (general), biological studies
Sesquiterpenes
Tannins
Vitamins
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antimicrobial prevention and treatment of human immunodeficiency virus
and other infectious diseases)

IT Alkylbenzyldimethylammonium chlorides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antimicrobial prevention and treatment of human immunodeficiency virus
and other infectious diseases)

IT Rectum
(anus, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Encephalitis
Meningitis
(bacterial and viral; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Detergents
(cationic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Inflammation
(cellulitis; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Polyacetylenes, biological studies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(derivs.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Animal tissue
(periacinal, administration to; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Plant (Embryophyta)
(phytochems.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Oral drug delivery systems
(sublingual; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Quaternary ammonium compounds, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactant; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetraenoic; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT Vitamins
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(water-sol.; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

IT 50-81-7, Ascorbic acid, biological studies 57-10-3, Hexadecanoic acid, biological studies 57-88-5, Cholesterol, biological studies 58-86-6, Xylose, biological studies 59-23-4, Galactose, biological studies 59-30-3, Folic acid, biological studies 59-43-8, Thiamin, biological studies **59-67-6**, Niacin, biological studies 64-19-7, Acetic

acid, biological studies 68-19-9, Vitamin B12 76-49-3, Bornyl acetate
79-83-4, Vitamin B5 80-56-8, .alpha.-Pinene 83-46-5,
.beta.-Sitosterol
83-48-7, Stigmasterol 83-88-5, Riboflavin, biological studies
87-44-5,
Caryophyllene 87-69-4 97-53-0, Eugenol 104-55-2, Cinnamaldehyde
108-39-4, biological studies 112-85-6D, Docosanoic acid, derivs.
117-39-5, Quercetin 121-33-5, Vanillin 122-03-2, Cuminaldehyde
127-91-3, .beta.-Pinene 138-86-3, Limonene 147-81-9, Arabinose
153-18-4, Rutin 327-97-9, Chlorogenic acid 331-39-5, Caffeic acid
331-39-5D, Caffeic acid, esters 474-58-8 474-62-4, Campesterol
480-10-4, Kaempferol-3-glucoside 482-35-9, Quercetin-3-glucoside
482-36-0 491-70-3, Luteolin 495-62-5, .gamma.-Bisabolene 504-97-2,
Echinacein 507-70-0, Borneol 520-18-3, Kaempferol 520-36-5,
Apigenin
534-61-2, Isochlorogenic acid 536-60-7, Cumic alcohol 548-75-4,
Quercetagetin-7-glucoside 563-83-7 593-50-0, n-Triacontanol
604-80-8
638-96-0, .alpha.-Amyrone 639-99-6, Elemol 643-20-9D, Pyrrolizidine,
alkaloid 1139-30-6, Caryophyllene epoxide 1406-16-2, Vitamin D
1406-18-4, Vitamin E 2450-53-5, 3,5-Dicaffeoylquinic acid 3562-36-5,
Pontica epoxide 3615-41-6, Rhamnose 3812-32-6, Carbonate, biological
studies 3943-97-3, Methyl p-hydroxycinnamate 4120-73-4,
4-O-Methylglucuronic acid 5373-11-5, Luteolin-7-glucoside 5937-48-4,
3-epi-.alpha.-Amyrin 6537-80-0, Chicoric acid 6556-12-3, Glucuronic
acid 7235-40-7, .beta.-Carotene 7439-89-6, Iron, biological studies
7439-95-4, Magnesium, biological studies 7439-96-5, Manganese,
biological studies 7440-09-7, Potassium, biological studies
7440-23-5,
Sodium, biological studies 7440-48-4, Cobalt, biological studies
7440-70-2, Calcium, biological studies 7723-14-0, Phosphorus,
biological
studies 7782-49-2, Selenium, biological studies 8001-18-1, Echinacin
8059-24-3, Vitamin B6 9005-80-5, Inulin 9014-63-5D, Xylan, derivs.
9036-66-2, Arabinogalactan 9040-28-2, 4-O-Methylglucuronoarabinoxylan
11006-56-7, Vitamin B15 11103-57-4, Vitamin A 12001-79-5, Vitamin K
12627-13-3, Silicate 13360-61-7, 1-Pentadecene 14808-79-8, Sulfate,
biological studies 16887-00-6, Chloride, biological studies
17627-44-0, .alpha.-Bisabolene 17650-84-9 18668-90-1,
8-Pentadecen-2-one 18794-84-8, .beta.-Farnesene 19912-61-9,
Furanodiene 20493-56-5, Curzerenone 23986-74-5, Germacrene D
24268-41-5, Furanodienone 24738-51-0 25067-58-7, Polyacetylene
25067-58-7D, Polyacetylene, derivs. 27214-55-7, Quercetin-3-xyloside
28028-64-0, Germacrene 29350-73-0, Cadinene 30964-13-7, Cynarin
36129-21-2 39007-92-6, Commiferin 47705-70-4 52525-35-6
57378-72-0
59440-97-0, Echinolone 61276-17-3, Verbascoside 67879-58-7
69350-61-4, Epishyobunol 74282-22-7 75081-19-5, Pentadecadiene
76963-26-3 80151-77-5, Tussilagine 82854-37-3, Echinacoside
84744-28-5 91108-32-6, Isotussilagine 94977-38-5 99119-75-2
99119-76-3 116752-09-1 116752-10-4 117841-81-3 118853-85-3
125199-93-1 148879-89-4, Commiphorinic acid 149531-55-5,
.alpha.-Commiphoric acid 149531-56-6, .beta.-Commiphoric acid
149531-57-7, .gamma.-Commiphoric acid 162666-19-5, Inuloidin
205510-62-9, Echinacin B 214041-69-7 214041-70-0 214041-71-1
214041-72-2 214041-73-3 214405-10-4, Heerabolene 214405-11-5,
.alpha.-Heerabomyrrhol 214405-12-6, .beta.-Heerabomyrrhol
214405-13-7,
Heeraboresene 214405-44-4, Viracea 1 214405-45-5, Viracea 2
RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(antimicrobial prevention and treatment of human immunodeficiency
virus

and other infectious diseases)
IT 120-32-1, o-Benzyl-p-chlorophenol 139-07-1, Lauryldimethylbenzylammonium chloride 5538-94-3, Dioctyldimethylammonium chloride 7173-51-5, Didecyldimethylammonium chloride 32426-11-2, Octyldecyldimethylammonium chloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)
IT 12001-76-2, Vitamin B
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(complex; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)
IT 79-14-1D, Glycolic acid, derivs.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(surfactant; antimicrobial prevention and treatment of human immunodeficiency virus and other infectious diseases)

=> d his

(FILE 'HOME' ENTERED AT 12:05:27 ON 23 JUL 2001)

FILE 'REGISTRY' ENTERED AT 12:05:31 ON 23 JUL 2001
E NIACIN
L1 15 S E3
L2 15 S NIACIN
E NIACIN
L3 5 S E4

FILE 'CAPLUS' ENTERED AT 12:06:43 ON 23 JUL 2001
L4 13365 S L1
L5 5592 S L3
L6 48143 S HIV OR RETROVIRUS
L7 30 S L4 AND L6
L8 9 S L5 AND L6

=> s l8 not l7

L9 0 L8 NOT L7

=> s hsv or herpes

8165 HSV
19185 HERPES
L10 20090 HSV OR HERPES

=> s l5 and l10

L11 5 L5 AND L10

=> d l11 1-5

L11 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 1998:648554 CAPLUS
DN 130:20311
TI Cytodifferentiating agents affect the replication of **herpes** simplex virus type 1 in the absence of functional VP16
AU Preston, Chris M.; McFarlane, Morag

CS Medical Research Council Virology Unit, Glasgow, G11 5JR, UK
SO Virology (1998), 249(2), 418-426
CODEN: VIRLAX; ISSN: 0042-6822
PB Academic Press
DT Journal
LA English
RE.CNT 43
RE
(1) Ace, C; J Virol 1989, V63, P2260 CAPLUS
(3) Breslow, R; Proc Natl Acad Sci USA 1991, V88, P5542 CAPLUS
(4) Chen, W; Proc Natl Acad Sci USA 1997, V94, P5798 CAPLUS
(5) Daksis, J; Virology 1992; V189, P196 CAPLUS
(6) Devary, Y; Mol Cell Biol 1991, V11, P2804 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 1998:293397 CAPLUS
DN 128:326546
TI Methods and compositions for dietary supplementation
IN Burgstiner, Carson B.
PA Burgstiner, Jacqueline Cook, USA
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9818491	A1	19980507	WO 1997-US19564	19971028
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI US 1996-29403		19961028		

L11 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 1994:116856 CAPLUS
DN 120:116856
TI Nitrous oxide-containing dermatological composition
IN Meyer, Petrus Johannes
PA Pitmy International N.V., Neth.
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9325213	A1	19931223	WO 1993-EP1405	19930603
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9343225	A1	19940104	AU 1993-43225	19930603
AU 667549	B2	19960328		
EP 644766	A1	19950329	EP 1993-912877	19930603
EP 644766	B1	19990317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
JP 08500092	T2	19960109	JP 1993-501088	19930603
AT 177642	E	19990415	AT 1993-912877	19930603
ES 2132236	T3	19990816	ES 1993-912877	19930603
NO 9404719	A	19941207	NO 1994-4719	19941207
US 5633284	A	19970527	US 1995-318626	19950213

PRAI ZA 1992-4153 19920608
AZ 1992-924153 19920608
WO 1993-EP1405 19930603

L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 1993:182853 CAPLUS
DN 118:182853
TI Antiviral properties of various drugs
AU Amvrosyeva, T. V.; Votyakov, V. I.; Vladyko, G. V.; Andreeva, O. T.; Vervetchenko, S. G.; Goretskaya, I. S.; Klimashevskaya, L. M.
CS Beloruss. Res. Inst. Epidemiol. Microbiol., Minsk, Belarus
SO Antibiot. Khimioter. (1992), 37(11), 5-8
CODEN: ANKHEW; ISSN: 0235-2990
DT Journal
LA Russian

L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 1982:168754 CAPLUS
DN 96:168754
TI Multivitamin for treating **herpes** infections
IN Girard, Michele; Baufle, Marie Chantal
PA Fr.
SO Fr. Demande, 8 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2484257	A1	19811218	FR 1980-13665	19800616
	FR 2484257	B3	19830311		

=> d l11 1 2 4 5 all

L11 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 1998:648554 CAPLUS
DN 130:20311
TI Cytodifferentiating agents affect the replication of **herpes** simplex virus type 1 in the absence of functional VP16
AU Preston, Chris M.; McFarlane, Morag
CS Medical Research Council Virology Unit, Glasgow, G11 5JR, UK
SO Virology (1998), 249(2), 418-426
CODEN: VIRLAX; ISSN: 0042-6822
PB Academic Press
DT Journal
LA English
CC 1-6 (Pharmacology)
Section cross-reference(s): 14
AB The **herpes** simplex virus type 1 (**HSV**-1) mutant in1814 encodes an altered form of the virion protein VP16 that is unable to transactivate immediate-early (IE) transcription. As a consequence of the mutation, in1814 initiates productive replication inefficiently after infection of tissue culture cells. Previous studies showed that this defect could be overcome by the inclusion in the culture medium of hexamethylene bisacetamide (HMBA), a compd. that promotes the differentiation of murine erythroleukemia cells (MELCs). The effects of addnl. agents known to induce differentiation of MELCs were investigated. N'-Methylnicotinamide, at concns. optimal for the induction of MELCs, complemented the replication of in1814 and stimulated IE gene expression. Suberoyl bishydroxamic acid and suberoylanilide hydroxamic acid, which

induce differentiation of MELCs at micromolar concns., did not complement in1814 but specifically blocked the action of HMBA. The histone deacetylase inhibitor trichostatin A, which also induces differentiation of MELCs, antagonized the effect of HMBA in a manner similar to that of suberoyl bishydroxamic acid and suberoylanilide hydroxamic acid. The results demonstrate that the requirement for VP16 activity is dependent on the metabolic state of the host cell and that the pathways leading to complementation of in1814 and differentiation of MELCs are overlapping but not identical. (c) 1998 Academic Press.

ST cytodifferentiating agent **herpes** simplex virus replication VP16 protein

IT Differentiation inducers
Erythroleukemia
Human herpesvirus 1
(cytodifferentiating agents affect replication of **herpes** simplex virus type 1 in absence of functional VP16 in relation to differentiation of erythroleukemia cells in relation to immediate-early gene transcription)

IT Immediate early genes (animal)
VP16 transcription factor
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(cytodifferentiating agents affect replication of **herpes** simplex virus type 1 in absence of functional VP16 in relation to differentiation of erythroleukemia cells in relation to immediate-early gene transcription)

IT **98-92-0**, Nicotinamide 114-33-0, N'-Methylnicotinamide 3073-59-4, Hexamethylene bisacetamide 3106-60-3, 1-Methylnicotinamide 3222-47-7, 6-Methylnicotinic acid 6960-22-1, 6-Methylnicotinamide 38937-66-5 58880-19-6, Trichostatin A 149647-78-9
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(cytodifferentiating agents affect replication of **herpes** simplex virus type 1 in absence of functional VP16 in relation to differentiation of erythroleukemia cells in relation to immediate-early gene transcription)

RE.CNT 43

RE

(1) Ace, C; J Virol 1989, V63, P2260 CAPLUS
(2) Bernstein, D; Arch Virol 1988, V99, P57 MEDLINE
(3) Breslow, R; Proc Natl Acad Sci USA 1991, V88, P5542 CAPLUS
(4) Chen, W; Proc Natl Acad Sci USA 1997, V94, P5798 CAPLUS
(5) Daksis, J; Virology 1992, V189, P196 CAPLUS
(6) Devary, Y; Mol Cell Biol 1991, V11, P2804 CAPLUS
(7) Dion, L; Virology 1997, V231, P201 CAPLUS
(8) Durkacz, B; Nature 1980, V283, P593 CAPLUS
(9) Ecob-Prince, M; J Gen Virol 1995, V76, P1527 CAPLUS
(10) Everett, R; Anticancer Res 1987, V7, P589 CAPLUS
(11) Everett, R; J Gen Virol 1989, V70, P1185 CAPLUS
(12) Everett, R; J Mol Biol 1993, V234, P1038 CAPLUS
(13) Harris, R; J Gen Virol 1991, V72, P907 CAPLUS
(14) Harris, R; J Virol 1989, V63, P3513 CAPLUS
(15) Honess, R; J Virol 1974, V14, P8 CAPLUS
(16) Jamieson, D; J Gen Virol 1995, V76, P1417 CAPLUS
(17) Kiyokawa, H; Proc Natl Acad Sci USA 1993, V90, P6746 CAPLUS
(18) Leib, D; J Virol 1989, V63, P759 CAPLUS
(19) MacLean, C; J Gen Virol 1991, V72, P897 CAPLUS
(20) Marks, P; Proc Natl Acad Sci USA 1994, V91, P10251 CAPLUS
(21) McFarlane, M; J Gen Virol 1992, V73, P285 CAPLUS

(22) Minegishi, N; J Biol Chem 1994, V269, P27700 CAPLUS
(23) Notarianni, E; Virology 1982, V123, P113 CAPLUS
(24) O'Hare, P; Semin Virol 1993, V4, P145 CAPLUS
(25) O'Rourke, D; J Virol 1993, V67, P7201 CAPLUS
(26) Preston, C; J Gen Virol 1998, V79, P117 CAPLUS
(27) Preston, C; J Virol 1997, V71, P7807 MEDLINE
(28) Ralph, W; J Virol 1994, V68, P6871 CAPLUS
(29) Ramsay, R; Proc Natl Acad Sci USA 1986, V83, P6849 CAPLUS
(30) Reuben, R; Biochim Biophys Acta 1980, V605, P325 CAPLUS
(31) Richon, V; Proc Natl Acad Sci USA 1996, V93, P5705 CAPLUS
(32) Richon, V; Proc Natl Acad Sci USA 1998, V95, P3003 CAPLUS
(33) Samaniego, L; J Virol 1998, V72, P3307 CAPLUS
(34) Sancar, A; Annu Rev Biochem 1988, V57, P29 CAPLUS
(35) Sanchez-Pacheco, A; FEBS Lett 1992, V312, P42 CAPLUS
(36) Stein, B; Photochem Photobiol 1992, V55, P409 CAPLUS
(37) Stowell, J; J Med Chem 1995, V38, P1411 CAPLUS
(38) Tal-Singer, R; J Virol 1997, V71, P5268 CAPLUS
(39) Tereda, M; Proc Natl Acad Sci USA 1979, V76, P6411
(40) Valyi-Nagy, T; J Virol 1991, V65, P4142 CAPLUS
(41) Whitby, A; Arch Virol 1987, V97, P137 CAPLUS
(42) Yoshida, M; Cancer Res 1987, V47, P3688 CAPLUS
(43) Yoshida, M; J Biol Chem 1990, V265, P17174 CAPLUS

L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 1998:293397 CAPLUS
DN 128:326546
TI Methods and compositions for dietary supplementation
IN Burgstiner, Carson B.
PA Burgstiner, Jacqueline Cook, USA
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K047-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 17
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9818491	A1	19980507	WO 1997-US19564	19971028

W: CA, JP, US
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRAI US 1996-29403 19961028

AB The present invention provides a compn. comprising thymic-derived factors and enzymic co-factors, wherein the thymic-derived factors can be thymus ext., thymus enzymic polypeptide factors, thymosin, thymopoietin and thymic humoral factor and the enzymic co-factors can be vitamins A, C, D, E, B-1, B-2, B-6, B-12, minerals. The compn. can also comprise amino acids which can be arginine, cysteine, histidine, ornithine, isoleucine, leucine, threonine, tyrosine, valine, phenylalanine and methionine. The compn. of this invention can further comprise glandular factors which can be raw spleen, raw lymph, raw bone marrow and raw pituitary. Also provided are methods of increasing serum levels of thymosin alpha 1 in a subject; of enhancing the immune system of a subject by increasing serum levels of thymosin alpha 1 in the subject; of treating an autoimmune disease such as systemic lupus erythematosus, multiple sclerosis and rheumatoid arthritis in a subject; of treating a viral infection caused by a virus such as Hepatitis A virus, hepatitis B virus, **herpes** virus, hepatitis C virus and human immunodeficiency virus in a subject; and of enhancing athletic performance in a subject by increasing hematocrit and reducing recovery time in the subject, wherein all of these

methods comprise administering to the subject the compns. of the present invention.
ST dietary supplement compn; vitamin dietary supplement compn; amino acid dietary supplement compn
IT Autoimmune diseases
Bone marrow
Lymph
Multiple sclerosis
Pituitary gland
Rheumatoid arthritis
Spleen
Systemic lupus erythematosus
Thymus gland
(dietary supplement compns.)
IT Amino acids, biological studies
Minerals, biological studies
Peptides, biological studies
Vitamins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dietary supplement compns.)
IT AIDS (disease)
Hepatitis A virus
Hepatitis B virus
Hepatitis C virus
Human herpesvirus
Human immunodeficiency virus
(infection; dietary supplement compns.)
IT Diet
(therapeutic; dietary supplement compns.)
IT 50-81-7, Vitamin C, biological studies 52-90-4, L-Cysteine, biological studies 56-87-1, L-Lysine, biological studies 58-85-5, Biotin 59-30-3, Folic acid, biological studies 59-43-8, Vitamin B1, biological studies 60-18-4, L-Tyrosine, biological studies 61-90-5, L-Leucine, biological studies 62-49-7, Choline 63-68-3, L-Methionine, biological studies 63-91-2, L-Phenylalanine, biological studies 68-19-9, Vitamin B12 70-26-8, L-Ornithine 71-00-1, L-Histidine, biological studies 72-18-4, L-Valine, biological studies 72-19-5, L-Threonine, biological studies 73-32-5, L-Isoleucine, biological studies 74-79-3, L-Arginine,
biological studies 79-83-4, Pantothenic acid 83-88-5, Vitamin B2, biological studies 87-89-8, Inositol **98-92-0**, Niacinamide 150-13-0, p-Aminobenzoic acid 153-18-4, Rutin 520-26-3, Hesperidin 590-46-5, Betaine hydrochloride 1406-16-2, Vitamin D 1406-18-4, Vitamin E 7439-95-4, Magnesium, biological studies 7439-96-5, Manganese, biological studies 7440-09-7, Potassium, biological studies 7440-42-8, Boron, biological studies 7440-47-3, Chromium, biological studies 7440-50-8, Copper, biological studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 7553-56-2, Iodine, biological studies 7782-49-2, Selenium, biological studies 8059-24-3, Vitamin B6 9001-73-4, Papain 9002-07-7, Trypsin 11103-57-4, Vitamin A 60529-76-2, Thymopoietin 61512-21-8, Thymosin 63340-72-7, Thymic humoral factor 68580-63-2, Octacosanol 150977-36-9,
Bromelain
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dietary supplement compns.)

L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 1993:182853 CAPLUS
DN 118:182853
TI Antiviral properties of various drugs
AU Amvrosyeva, T. V.; Votyakov, V. I.; Vladyko, G. V.; Andreeva, O. T.; Vervetchenko, S. G.; Goretskaya, I. S.; Klimashevskaya, L. M.

CS Beloruss. Res. Inst. Epidemiol. Microbiol., Minsk, Belarus
SO Antibiot. Khimioter. (1992), 37(11), 5-8
CODEN: ANKHEW; ISSN: 0235-2990
DT Journal
LA Russian
CC 1-5 (Pharmacology)
AB The cardiovascular drugs nicotinamide, strophanthin, corglycone, curantyl,
cavinton, papaverine, nicotinic acid, xanthinol nicotinate, isoptin, parmidine, and halidor were screened for antiviral effects. Most of them (9 of 11) had an activity which was rather individual by its specificity and level. Lab. strains of **herpes** simplex, variola, influenza, vesicular stomatitis, respiratory syncytial infection, Venezuelan equine encephalitis, ECHO, Lassa fever, and rota viruses were tested. The characteristic feature of the drugs was their high specific activity against the DNA viruses and rotavirus. Papaverine, strophanthin, and corglycone were most promising. Their antiviral activity was confirmed in
a model **herpes** infection in mice. The clin. implications of these virucidal side-effects are discussed.
ST cardiovascular drug virucide side effect
IT Virucides and Virustats
(cardiovascular drugs as)
IT Cardiovascular agents
(virucidal effects of)
IT 52-53-9, Isoptin 58-32-2, Curantyl 58-74-2, Papaverine 59-67-6, Nicotinic acid, biological studies **98-92-0**, Nicotinamide 437-74-1, Xanthinol nicotinate 508-75-8, Corglycone 1882-26-4, Parmidine 11005-63-3, Strophanthin 14286-84-1, Halidor 42971-09-5, Cavinton
RL: PRP (Properties)
(virucidal effects of)

L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 1982:168754 CAPLUS
DN 96:168754
TI Multivitamin for treating **herpes** infections
IN Girard, Michele; Baufle, Marie Chantal
PA Fr.
SO Fr. Demande, 8 pp.
CODEN: FRXXBL
DT Patent
LA French
IC A61K031-66; A61K031-07; A61K031-59; A61K031-195; A61K031-335; A61K031-395
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2484257	A1	19811218	FR 1980-13665	19800616
FR 2484257	B3	19830311		

AB All cases of **herpes** (recurrent, labial, genital) could be treated rapidly and efficiently by a multivitamin compn. contg. vitamin A [11103-57-4] trace, vitamin D3 [67-97-0] trace, vitamin B1 [59-43-8] 1-5, vitamin B2 [83-88-5] 1-5, vitamin B5 [79-83-4] 1-5, vitamin B6 [8059-24-3] 0.5-1, vitamin B8 [64060-35-1] 0.01-0.05, vitamin B9 [11096-55-2] 0.05-0.1, vitamin B12 [68-19-9] 0.001-0.002, vitamin C [50-81-7] 20-50, vitamin E [1406-18-4] 2-10, and vitamin PP [11032-50-1]
0.01-0.02 mg.
ST **herpes** treatment multivitamin; vitamin **herpes** infection
IT Vitamins

RL: BIOL (Biological study)
(**herpes** infection treatment with, in humans)
IT Virus, animal
(**herpes**, infection with, multivitamin compn. for treatment of, in humans)
IT 58-56-0 58-85-5 58-95-7 59-30-3, biological studies **98-92-0** 137-08-6 146-17-8
RL: BIOL (Biological study)
(**herpes** infection treament with multivitamin compn. contg., in humans)
IT 50-81-7, biological studies 59-43-8, biological studies 67-97-0 68-19-9 79-83-4 83-88-5, biological studies 1406-18-4 8059-24-3 11032-50-1 11096-55-2 11103-57-4 64060-35-1
RL: BIOL (Biological study)
(**herpes** infection treatment with multivitamin compn. contg., in humans)

=> d his

(FILE 'HOME' ENTERED AT 12:05:27 ON 23 JUL 2001)

FILE 'REGISTRY' ENTERED AT 12:05:31 ON 23 JUL 2001
E NIACIN
L1 15 S E3
L2 15 S NIACIN
E NIACIN
L3 5 S E4

FILE 'CAPLUS' ENTERED AT 12:06:43 ON 23 JUL 2001
L4 13365 S L1
L5 5592 S L3
L6 48143 S HIV OR RETROVIRUS
L7 30 S L4 AND L6
L8 9 S L5 AND L6
L9 0 S L8 NOT L7
L10 20090 S HSV OR HERPES
L11 5 S L5 AND L10

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	79.80	91.97
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.06	-7.06

STN INTERNATIONAL LOGOFF AT 12:28:04 ON 23 JUL 2001